Navigation Links
Pivotal Study Validates Roche's cobas® HPV Test with HPV-16 and 18 Genotyping for Identifying Women at Highest Risk for Cervical Cancer
Date:2/24/2011

PLEASANTON, Calif., Feb. 24, 2011 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that a study published online today in the American Journal of Clinical Pathology demonstrated the ability of the cobas HPV Test to individually detect HPV-16 and HPV-18, two of the highest risk HPV genotypes causing 70 percent of cervical cancer cases. The ATHENA (Addressing THE Need for Advanced HPV Diagnostics) study, which involved more than 47,000 women, validates the cobas HPV Test for triage of patients with an equivocal Pap test, a cytology category indicating atypical cells of undetermined significance (ASC-US). This is the first in a series of papers to be published from the ATHENA study.

"At least four out-of five women in the U.S. will have been infected with HPV at some point in their lives, and it's critical to have early and accurate information about which individuals are at greatest risk for possible progression to cervical cancer," said Mark H. Stoler, MD, Professor and Associate Director of Surgical Pathology and Cytopathology, at the University of Virginia Health System. "Results from ATHENA demonstrated that the cobas HPV Test is a clinically valid tool for physicians needing to manage the ASC-US population as it identifies not only high-risk HPV, but also HPV-16/HPV-18 without additional tests. This ability to identify genotype-related risk will also be highly useful if revisions to ASC-US management guidelines are considered," concluded Dr. Stoler.

Results from the ATHENA study also demonstrated that the sensitivity of the cobas HPV Test was equivalent to the current standard of testing, while providing the added benefit of clinically valuable information regarding the HPV-16 and HPV-18 genotypes in a single test. Previously presented ATHENA data confirmed that the cobas HPV test detected cervical pre-cancer
'/>"/>

SOURCE Roche Diagnostics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
2. Positive SPA Reply From the FDA for TopoTargets Pivotal Trial With Belinostat in PTCL
3. Fifth DuraHeart(TM) U.S. Implant Marks Important Milestone in U.S. Pivotal Trial
4. Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial
5. Genmab A/S: Ofatumumab Pivotal CLL Data to be Presented at ASH
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point
7. BioSyntech to conclude enrolment for pivotal BST-CarGel(R) trial in February 2009
8. BioSyntech Achieves Enrolment Goal for Pivotal Trial of BST-CarGel(R), its Cartilage Repair Device
9. ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results
10. PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
11. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... VIEW, Calif. , Aug. 21, 2014 /PRNewswire/ ... properties and behaviors based on external stimuli such ... poised to have a disruptive effect in multiple ... revolutionize the business landscape by printing objects ranging ... aerospace and automotive sectors. Logo - ...
(Date:8/21/2014)... Louis, MO (PRWEB) August 21, 2014 ... full service biopharmaceutical contract development and manufacturing organization ... by Progenics Pharmaceuticals, Inc., an oncology company focused ... and treating cancer, to manufacture the anti-prostate specific ... PSMA ADC product candidate. Under the agreement ...
(Date:8/20/2014)... N.C. , Aug. 20, 2014 ... research services located in Raleigh, NC ... Bradford Evans as Vice President of Administration. ... Brad will oversee all corporate processes, including their ... joining Clintrax Global, Brad worked as an HR ...
(Date:8/20/2014)... succeeded in measuring vibrational motion of a single molecule ... vibration of a single molecule differs from the behaviour ... performed at the University of California, Irvine, where post-doctoral ... as a visiting fellow under professor Vartkess A. Apkarian, ... was lead by Professor Eric O. Potma. The results ...
Breaking Biology Technology:Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 4Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3Clintrax Global, Inc. Announces Addition to Executive Team 2Seeing a molecule breathe 2
... , SEATTLE, Dec. 6 A challenge donation from the ... total to more than $7 million for Fred Hutchinson Cancer Research ... during which guests raise their bid cards for specific contribution levels, ... work to harness the human immune system to battle cancer. ...
... , NEW YORK, Dec. 4 Stemline Therapeutics, Inc. ... agents, SL-401 and SL-501, in both in vitro and ... for poster presentation at the upcoming 51st Annual Meeting of the ... from December 5-8, 2009. The poster will be presented by Stemline,s ...
... Dec. 3 VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), ... the treatment of cardiovascular and metabolic disease, today announced that ... 2 FDG-PET clinical trial of VIA-2291. , The FDG-PET ... sites in the US and Canada including Massachusetts General Hospital, ...
Cached Biology Technology:34th Annual Hutch Holiday Gala Raises More Than $7 Million For Cancer Research 234th Annual Hutch Holiday Gala Raises More Than $7 Million For Cancer Research 3Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4
(Date:8/22/2014)... to purchase fuel cell cars from Toyota and other ... cars will run on hydrogen made from natural gas, ... Now scientists at Stanford University have developed a low-cost, ... produce hydrogen by water electrolysis. The battery sends ... water into hydrogen and oxygen gas. Unlike other water ...
(Date:8/21/2014)... BLOOMINGTON, Ind. -- A new study of American ... partner, men have the highest orgasm rates. On ... time, with their sexual orientation making little difference. ... On average, women experience orgasm 62.9 percent of ... -- and this pattern varies with women,s sexual ...
(Date:8/21/2014)... to dandruff, eczema and other itchy, flaky maladies in ... reachesincluding Hawaiian coral reefs and the extreme environments of ... in the scientific journal PLOS Pathogens considers ... the genus Malassezia in light of new ... the world. , University of Hawai,i at Mānoa scientist ...
Breaking Biology News(10 mins):Stanford scientists develop a water splitter that runs on an ordinary AAA battery 2Stanford scientists develop a water splitter that runs on an ordinary AAA battery 3Orgasm rates for single women less predictable than men's, vary by sexual orientation 2Orgasm rates for single women less predictable than men's, vary by sexual orientation 3Orgasm rates for single women less predictable than men's, vary by sexual orientation 4From dandruff to deep sea vents, an ecologically hyper-diverse fungus 2
... Athene Donald has won the Science and Technology award ... honor to Professor Donald, Glamour magazine praised her as a ... real path for herself in the male-dominated world of physics." ... Physics at the University of Cambridge in the United Kingdom ...
... CAA researcher at Charles Drew University of Medicine and Science ... a promising, natural therapy for cancer. Dr. Mamdooh Ghoneum ... on "Cell Death Mechanism," sponsored by the American Association for ... San Diego. "The central focus of the meeting ...
... RIVERSIDE, Calif. Stem cell research at the University of ... establishment of a new Stem Cell Core Facility (SCCF) ... doing stem cell research that ordinarily would not be available ... Noel Keen Hall, had its grand opening on Friday, Jan. ...
Cached Biology News:Charles Drew cancer studies with yeast yield excellent results 2UC Riverside's new state-of-the-art technology to accelerate stem cell research 2
... offers a full length insert sequencing service ... cosmids and fosmids. Agencourt utilizes unique ... libraries. There are several features that ... data with rapid turnaround including our patented ...
...
... Cytometry The Guava EasyCyte system is ... multiparameter cytometer with built-in 96-well microplate sampling ... plates of cells and compounds quickly and ... tubes or having the carryover issues found ...
A flexible 24-48 hour DNA sequencing service. Samples may be shipped in standard 1.5mL tubes. Oligo synthesis and DNA preparation available. Read lengths up to 850 Phred 20 bases. Universal primers p...
Biology Products: